• 1
    Hakama M. Trends in the incidence of cervical cancer in the Nordic Countries. In: MagnusK, editor. Trends in Cancer Incidence. Causes and Practical Implications. New York: Hemisphere, 1982: 279292.
  • 2
    Läärä E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries; Association with organised screening programmes. Lancet 1987;I: 12471249.
  • 3
    Nieminen P, Kallio M, Hakama M. Effect of mass-screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995;85: 10171021.
  • 4
    Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case control study. Int J Cancer 1999;83: 5558.
  • 5
    Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life up to the year 2017. Acta Oncol 1997;36(Suppl):160.
  • 6
    Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of oganised screening on cervical cancer incidence and mortality in Finland, 1963–1995: a recent increase in the incidence. Int J Cancer 1999;83: 5963.
  • 7
    ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cell of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92: 397402.
  • 8
    Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Br J Cancer 2000;83(5):561565.
  • 9
    Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95(1):4652 (January 1).
  • 10
    Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity and frequency of referral. JAMA 2002;288(14):17491757 (October 9).
  • 11
    Nieminen P, Viikki M, Hakama M, Tarkkanen J, Anttila A. Prospective and randomised public-health trial on neural network-assisted screening for cervical cancer in Finland: results of the first year. Int J Cancer 2003;103: 422426.
  • 12
    Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84(12):16161623 (June 15).
  • 13
    Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002;95(10):21452151 (November 15).
  • 14
    Breast Cancer Screening. IARC Handbooks of Cancer Prevention. Lyon: IARC, 2002 (229 pp).
  • 15
    Lorincz A, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127: 959968.
  • 16
    Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96(4):280293 (February 18).
  • 17
    Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362(9399):18711876 (December 6).